News
NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Transgene Reports Q1 2020 Financial Position and Business Update
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business
Premier Inc. Puts Unmatched Insights at Clinicians’ Fingertips with Launch of Perinatal Quality Dashboard
Premier Inc. (NASDAQ: PINC) is advancing care for mothers and infants with the launch of its Perinatal Quality Dashboard that delivers self-service, actionable insights to support clinicians on the
Humana Jumps 17 Spots on Benchmark List of Top 50 Companies for Diversity
Humana Inc. (NYSE: HUM) rose dramatically on the DiversityInc list of Top 50 Companies for Diversity, jumping 17 spots in making the list for the third year in a row. The list honors leadership in
Clovis Oncology Announces First Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and
Premier Inc. Reports Fiscal 2020 Third-Quarter Results
Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 third quarter ended March 31, 2020.
All results presented in this press release reflect continuing operations
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to
Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development
Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development
Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development
Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development
Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development
Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development
Acadia Healthcare Reports First Quarter 2020 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2020, and provided an update on the impact of the COVID-19 pandemic.
Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes
Humana-Owned Health Care Facilities Implement New COVID-19 Prevention Standards
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that its senior-focused primary care subsidiaries Conviva Care Centers, Partners in Primary Care, and Family Physicians
New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized
Pfizer Inc. (NYSE:PFE) today announced detailed results of the first study to show the burden of both invasive and non-invasive Group B Streptococcus infections (GBS) among hospitalized adults in
New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized
Pfizer Inc. (NYSE:PFE) today announced detailed results of the first study to show the burden of both invasive and non-invasive Group B Streptococcus infections (GBS) among hospitalized adults in
Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses
Regulatory News:
Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s (Paris:TNG) proprietary DuckCelt®-T17 cell line.
Savara to Report First Quarter 2020 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020
Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.
First quarter 2020 results:
-
Revenue of $859 million, a 2% increase compared to
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.
First quarter 2020 results:
-
Revenue of $859 million, a 2% increase compared to
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.
First quarter 2020 results:
-
Revenue of $859 million, a 2% increase compared to
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs and digital therapeutics, have
NANOBIOTIX Announces First Quarter 2020 Revenues
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of
Premier Inc. Data: As COVID-19 Cases Spike, Demand for Drugs Used to Treat Related, Co-Morbid Conditions Also Soars
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released new data finding that as COVID-19 cases peak, so does demand for drugs used to treat cardiovascular conditions